Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
REGULATORY
MHLW Seeks Record 36.6 Trillion Yen for FY2027, Puts AI in Focus
Japan’s Ministry of Health, Labor and Welfare (MHLW) is seeking a record 36.58 trillion yen from the general account for FY2027, up 1.54 trillion yen from the initial FY2026 budget, with major new investments planned in AI-driven drug discovery and…
To read the full story
Related Article
- FPMAJ Lauds Drug Investment Push, Urges Budget Follow-Through
September 8, 2026
- MHLW Seeks at Least 275 Billion Yen to Shore Up Drug Supplies
September 7, 2026
- MHLW Lines Up 32.6 Billion Yen for 4 New Drug Discovery Support Projects
September 2, 2026
- MHLW Seeks 13.9 Billion Yen to Boost Domestic Biosimilar Production
September 2, 2026
- Cabinet Office Seeks 22 Billion Yen for Clinical Trial Subsidies
September 1, 2026
- MHLW Tax Reform Requests Cover Support for MCM Preparedness
August 28, 2026
- MHLW Pharma Bureau Eyes 12 Billion Yen to Boost Plasma Product Production
August 28, 2026
- Outgoing MHLW Pharmacy Chief Eyes AI as Next Frontier for Drug Regulation
August 4, 2026
- No Cap on FY2027 Budget Requests under Growth Investment Scheme: MOF
July 29, 2026
- MHLW Sets FY2027 Budget Priorities for Drug Discovery, Advanced Medicine
July 28, 2026
- iPark Eyes Shared AI Platform to Keep Japan in Global Drug Discovery Race
July 14, 2026
- iPark CEO Calls for National AI Drug Discovery Platform at LDP Hearing
June 12, 2026
REGULATORY
- MHLW to Weigh Survey Data, Past Approach for FY2027 Revision: Official
September 10, 2026
- Chuikyo Reps Back Greater Transparency, but Lean toward Broader CEA Price Cuts
September 10, 2026
- OTC-Like Drug Charge Gets Prescription Field; No Double Charge with LLP Rule
September 10, 2026
- Defense Chief Seeks MHLW Help Securing Drugs for SDF
September 9, 2026
- PMDA Generic GMP Inspections a Real-World Test to Stem Startup Risks: Official
September 8, 2026
Japanese Prime Minister Sanae Takaichi has pledged to respond to the US most-favored-nation (MFN) drug pricing policy to safeguard timely…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…